The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Learn more about the discovery of insulin and the controversy this life-saving medicine sparked.

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound ... it has also started to offer compounded versions of Novo Nordisk's GLP-1 agonist drug semaglutide ...